Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

NCT00935012 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer